) Transcriptional regulators control much of development by regulating cascades of gene expression. Since neoplasia is similar to a disrupted developmental process, it is not surprising that the vast majority of genetic lesions in neoplasia have been aberrant transcriptional regulators. Transcriptional regulators fall into families based on shared amino acid sequences in the DNA binding domains. One such group that has been shown to be important in both development and neoplasia is the winged helix family (formerly called HNF-3/Forkhead) of transcriptional regulators. We have cloned and characterized a novel member of this family, called Genesis, that is important in normal and malignant germ cell development. The hypothesis underlying this proposal is that Genesis regulates the fundamental decision of growth versus differentiation in normal or malignant embryonic stem cells. This proposal will investigate the role of Genesis in germ cell malignancies in four specific aims. First, the biochemistry of transcriptional regulation by Genesis will be investigated using GAL4 and heterologous promoter assays. Second, targets for Genesis interaction will be identified using the two hybrid system and genomic binding site selection. In addition, there are four promoters of transcriptional regulators (HNF-3 beta, Hox A4, Hox B4, and Hox-7) which have potential Genesis binding sites, and are expressed in a manner that indicates possible Genesis regulation. These will be analyzed using co-transfection assays. Third, the phenotypic changes regulated by Genesis in embryonal stem and carcinoma cells will be analyzed in gain-of-function or loss-of-function experiments. The effect of Genesis under-expression (homologous recombination knock-outs) or forced over-expression (retroviral transduction) will be studied. Fourth, since Genesis is located at chromosome 1p31, a region of consistent abnormalities in testicular carcinoma, the structure and expression of Genesis in germ cell neoplasia will be explored. Completion of these aims will provide insight into the function of Genesis in normal versus malignant embryonic stem cell development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA074295-03
Application #
6493050
Study Section
Project Start
2001-08-22
Project End
2003-07-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
$254,104
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Juric, Dejan; Sale, Sanja; Hromas, Robert A et al. (2005) Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci U S A 102:17763-8
George, David W; Foster, Richard S; Hromas, Robert A et al. (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21:113-22
Madani, A; Kemmer, K; Sweeney, C et al. (2003) Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 14:873-80
Guo, Ying; Costa, Robert; Ramsey, Heather et al. (2002) The embryonic stem cell transcription factors Oct-4 and FoxD3 interact to regulate endodermal-specific promoter expression. Proc Natl Acad Sci U S A 99:3663-7
Soule, S; Baldridge, L; Kirkpatrick, K et al. (2002) HER-2/neu expression in germ cell tumours. J Clin Pathol 55:656-8
Richkind, K; Hromas, R; Lytle, C et al. (2000) Identification of two new translocations that disrupt the AML1 gene. Cancer Genet Cytogenet 122:141-3
Hromas, R; Shopnick, R; Jumean, H G et al. (2000) A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood 95:4011-3